Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) 5-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Shanxi C&Y Pharmaceutical Group Co 5-Year EBITDA Growth Rate?

Shanxi C&Y Pharmaceutical Group Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shanxi C&Y Pharmaceutical Group Co was 54.00% per year. The lowest was -36.70% per year. And the median was -6.25% per year.

Competitive Comparison of Shanxi C&Y Pharmaceutical Group Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shanxi C&Y Pharmaceutical Group Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanxi C&Y Pharmaceutical Group Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanxi C&Y Pharmaceutical Group Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shanxi C&Y Pharmaceutical Group Co's 5-Year EBITDA Growth Rate falls into.

Shanxi C&Y Pharmaceutical Group Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Shanxi C&Y Pharmaceutical Group Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shanxi C&Y Pharmaceutical Group Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanxi C&Y Pharmaceutical Group Co Ltd (SZSE:300254) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

No.53, Hubin Street, Economic and Technological Development Zone, Datong, CHN, 037010

Website

http://www.cy-pharm.com

Shanxi C&Y Pharmaceutical Group Co Ltd is engaged in the production, research and development, and sales of pharmaceutical products. The company offers pregnancy products and services, anti-infective, and urinary health.

Executives

Zuo Xue Min	Supervisors
Huang Le Qun	Director
Zhang Zhen Biao	Executives
Yu Jun Xian	Directors, Directors, and Executives
Zhao Qun	Director
Weng Zhan Guo	Director
Geng Chun Feng	Director
Pang Xiao Quan	Supervisors
Zhong Hai Rong	Directors, executives
Xuan Hang	Director

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Headlines

No Headlines